newsfilter
← Latest News
ACCESS Newswire·

Moderna Outlines Next Phase of Growth at Analyst Day

MRNA
  • Moderna outlined growth strategies at its 2026 Analyst Day, highlighting intismeran & cancer antigen therapies as foundational oncology opportunities following positive Phase 3 results in adjuvant melanoma.
  • The company is preparing for broader commercial launch of mFLUSIVA® during the 2027-2028 respiratory season after approvals in the U.S. & Canada in 2026.
  • Moderna plans to expand in Europe as competitor contracts expire, leveraging four approved respiratory vaccines & new agreements in Mexico & Taiwan.
  • The Marlborough, Massachusetts facility began supplying intismeran clinical material in September 2025 & is scheduled to become the global supply site in 2027.
  • Intismeran commercialization will utilize a co-promotion model where Merck leads outside the U.S. while combining Merck's oncology infrastructure with Moderna's capabilities in the U.S.
  • Intismeran demonstrated a 42% reduction in recurrence or death risk & a 38% reduction in distant metastasis or death risk compared to KEYTRUDA alone in the Phase 3 INTerpath-001 study.
  • Moderna expects 2026 revenue growth of 15% to 25% & approximately 10 percentage points of gross margin expansion excluding litigation charges.
  • The company accelerated cost reductions, targeting $4 billion in cash costs for 2027 with annual costs of $4 billion to $4.5 billion from 2027 through 2030.
  • Amended terms for a $1.5 billion credit facility with Ares Management extend maturity to 2031, extend borrowing capacity availability to 2029, & reduce interest rates by 75 basis points.
  • Moderna anticipates ending 2026 with approximately $9 billion in total liquidity while maintaining disciplined capital allocation toward oncology & emerging pipelines.
  • Artificial intelligence & automation are being integrated across the platform to accelerate scientific learning, improve development efficiency, & reduce manufacturing costs.
  • Additional pipeline updates include mNEXSPIKE® real-world effectiveness data, mCOFLU® approval in Canada, & Phase 4 studies for combination vaccines.
  • Emerging modalities such as mRNA-4194 for Lynch syndrome & T-cell engagers for multiple myeloma are advancing in early clinical development.
  • Formal 2027 financial guidance is expected during the fourth-quarter 2026 earnings call.
Company
Moderna, Inc.
Keywords
Healthcare & Pharmaceutical, Company Update